PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Arnold, Douglas L.
TI  - DECIDE: Significantly Improved Brain MRI Results with DAC HYP versus Interferon in RRMS
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 6--7
VI  - 14
IP  - 29
4099  - http://mdc.sagepub.com/content/14/29/6.short
4100  - http://mdc.sagepub.com/content/14/29/6.full
AB  - Daclizumab high-yield process (DAC HYP) is a humanized monoclonal antibody specific for CD25, the alpha subunit of the interleukin 2 receptor [Gold R et al. Lancet. 2013]. This article presents the magnetic resonance imaging (MRI) data from the phase 3 Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β1a in Patients With Relapsing-Remitting Multiple Sclerosis trial [DECIDE; NCT01064401].